Method for producing solid galenic formulations using a crosslinked non-thermoplastic carrier
    1.
    发明授权
    Method for producing solid galenic formulations using a crosslinked non-thermoplastic carrier 有权
    使用交联的非热塑性载体制备固体盖仑制剂的方法

    公开(公告)号:US07846477B2

    公开(公告)日:2010-12-07

    申请号:US10530483

    申请日:2003-10-09

    IPC分类号: A61K9/20 B27N3/00

    摘要: The invention concerns a method for producing solid galenic formulations which consists in: forming a processable paste comprising a) 50 to 99.4 wt. % of at least one non-thermoplastic carrier, b) 0.5 to 30 wt. % of at least an adjuvant selected among thermoplastic polymers, lipids, sugar alcohols and solubilizing agents, c) 0.1 to 49.5 wt. % of at least one active principle, at a temperature not less than the softening temperature of the adjuvant but rising to at least 70° C.; then in cooling the resulting paste. Said solid galenic formulations quickly disintegrate in an aqueous medium.

    摘要翻译: 本发明涉及一种制备固体盖仑制剂的方法,其中包括:形成可加工的糊剂,其包含a)50至99.4wt。 %的至少一种非热塑性载体,b)0.5〜30wt。 至少选自热塑性聚合物,脂质,糖醇和增溶剂中的佐剂的%,c)0.1至49.5wt。 %的至少一种活性成分,在不低于佐剂的软化温度但升至至少70℃的温度下。 然后冷却所得糊状物。 所述固体盖仑制剂在水性介质中快速崩解。

    Composition and Dosage Form Comprising a Solid or Semi-Solid Matrix
    2.
    发明申请
    Composition and Dosage Form Comprising a Solid or Semi-Solid Matrix 审中-公开
    包含固体或半固体基质的组合物和剂型

    公开(公告)号:US20090220596A1

    公开(公告)日:2009-09-03

    申请号:US11922609

    申请日:2006-06-22

    IPC分类号: A61K9/20 A61K9/10

    摘要: A composition which comprises a solid or semi-solid matrix having at least one active ingredient uniformly dispersed therein, the matrix comprising at least one pharmaceutically acceptable matrix-forming agent and a 1,3-bis(lactamyl)-butane compound, in particular 1,3-bis(pyrrolidon-1-yl)-butane. The active ingredient is preferably dispersed in the matrix in a state of a solid solution. The matrix-forming agent is preferably a pharmaceutically acceptable polymer. The composition is useful for the manufacture of pharmaceutical dosage forms.

    摘要翻译: 一种组合物,其包含固体或半固体基质,其具有均匀分散于其中的至少一种活性成分,所述基质包含至少一种药学上可接受的基质形成剂和1,3-双(内酰胺基) - 丁烷化合物,特别是1 ,3-双(吡咯烷酮-1-基) - 丁烷。 活性成分优选以固体状态分散在基质中。 基质形成剂优选为药学上可接受的聚合物。 该组合物可用于制备药物剂型。

    Method of producing solid dosage forms
    4.
    发明授权
    Method of producing solid dosage forms 有权
    生产固体剂型的方法

    公开(公告)号:US06737005B1

    公开(公告)日:2004-05-18

    申请号:US09831397

    申请日:2001-05-09

    IPC分类号: B26B102

    CPC分类号: A61J3/10 B30B11/165

    摘要: A process for producing solid dosage forms by a) producing a plastic mixture which comprises at least one active ingredient and at least one polymeric binder, and b) shaping the plastic mixture to the solid dosage forms in a molding calender with two counterrotating molding rolls, wherein one molding roll has at least one annular groove running along its periphery and the other molding roll has at least one ring, running along its periphery, of teeth extending radially outward and able to engage in the annular groove is described.

    摘要翻译: 一种生产固体剂型的方法,包括:a)制备包含至少一种活性成分和至少一种聚合物粘合剂的塑料混合物,以及b)使用两个反向旋转成型辊将塑料混合物在成型压延机中成形为固体剂型, 其中一个成型辊具有沿着其周边延伸的至少一个环形槽,并且另一个成型辊具有至少一个沿着其周边延伸的环,径向向外延伸并能够接合在环形槽中的环。

    Formulation based on heparin, glycosaminoglycan or heparinoid, use of the formulation and the formulation base
    8.
    发明授权
    Formulation based on heparin, glycosaminoglycan or heparinoid, use of the formulation and the formulation base 失效
    基于肝素,糖胺聚糖或类肝素的制剂,使用制剂和制剂基础

    公开(公告)号:US07393840B2

    公开(公告)日:2008-07-01

    申请号:US10296441

    申请日:2001-05-29

    IPC分类号: A61N31/747

    摘要: The present invention relates to formulations based on at least one heparin, glycosaminoglycan or heparinoid and on a formulation base with a lipid component and a polymer component. The use of this formulation as drug form for oral administration of at least one heparin, glycosaminoglycan or heparinoid, and also a process for producing the formulations by mixing the formulation components to form a plastic mixture and, where appropriate, to manufacture the formulations as drug form, advantageously using melt extrusion, are described. The lipid component advantageously has active ingredient-promoting properties, while the polymer component is soluble or swellable. At least parts of the lipid component are embedded in a polymer matrix, preferably in the form of a molecular dispersion. The formulations can form emulsions in water or aqueous liquids.

    摘要翻译: 本发明涉及基于至少一种肝素,糖胺聚糖或类肝素的制剂,以及具有脂质组分和聚合物组分的制剂基质。 使用这种制剂作为口服给药至少一种肝素,糖胺聚糖或类肝素的药物形式,以及通过混合制剂组分以形成塑料混合物并在适当时制备制剂作为药物来制备制剂的方法 描述了有利地使用熔体挤出的形式。 脂质组分有利地具有活性成分促进性质,而聚合物组分是可溶的或可溶胀的。 至少部分脂质组分嵌入聚合物基质中,优选以分子分散体的形式。 制剂可以在水或含水液体中形成乳液。